Seagen Inc. SGT.F Stock
Seagen Inc. Price Chart
Seagen Inc. SGT.F Financial and Trading Overview
| Seagen Inc. stock price | 208.6 EUR |
| Previous Close | 179.9 EUR |
| Open | 179.3 EUR |
| Bid | 179.5 EUR x 10000 |
| Ask | 181.4 EUR x 10000 |
| Day's Range | 179.3 - 179.3 EUR |
| 52 Week Range | 110.3 - 201.55 EUR |
| Volume | 28 EUR |
| Avg. Volume | 29 EUR |
| Market Cap | 33.85B EUR |
| Beta (5Y Monthly) | 0.522887 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
SGT.F Valuation Measures
| Enterprise Value | 32.48B EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 16.46902 |
| Price/Book (mrq) | 12.331499 |
| Enterprise Value/Revenue | 15.799 |
| Enterprise Value/EBITDA | -54.713 |
Trading Information
Seagen Inc. Stock Price History
| Beta (5Y Monthly) | 0.522887 |
| 52-Week Change | 29.87% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 201.55 EUR |
| 52 Week Low | 110.3 EUR |
| 50-Day Moving Average | 182.96 EUR |
| 200-Day Moving Average | 148.47 EUR |
SGT.F Share Statistics
| Avg. Volume (3 month) | 29 EUR |
| Avg. Daily Volume (10-Days) | 45 EUR |
| Shares Outstanding | 187.5M |
| Float | 141.51M |
| Short Ratio | N/A |
| % Held by Insiders | 0.90% |
| % Held by Institutions | 91.80% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -31.54% |
| Operating Margin (ttm) | -32.32% |
| Gross Margin | 10.64% |
| EBITDA Margin | -28.87% |
Management Effectiveness
| Return on Assets (ttm) | -11.60% |
| Return on Equity (ttm) | -22.67% |
Income Statement
| Revenue (ttm) | 2.06B EUR |
| Revenue Per Share (ttm) | 11.08 EUR |
| Quarterly Revenue Growth (yoy) | 21.89% |
| Gross Profit (ttm) | 207.99M EUR |
| EBITDA | -593609024 EUR |
| Net Income Avi to Common (ttm) | -648550976 EUR |
| Diluted EPS (ttm) | -3.2 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.49B EUR |
| Total Cash Per Share (mrq) | 7.95 EUR |
| Total Debt (mrq) | 104.89M EUR |
| Total Debt/Equity (mrq) | 3.85 EUR |
| Current Ratio (mrq) | 3.648 |
| Book Value Per Share (mrq) | 14.54 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -486582016 EUR |
| Levered Free Cash Flow (ttm) | -297927616 EUR |
Profile of Seagen Inc.
| Country | Germany |
| State | WA |
| City | Bothell |
| Address | 21823 30th Drive SE |
| ZIP | 98021 |
| Phone | 425 527 4000 |
| Website | https://www.seagen.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 3256 |
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Q&A For Seagen Inc. Stock
What is a current SGT.F stock price?
Seagen Inc. SGT.F stock price today per share is 208.6 EUR.
How to purchase Seagen Inc. stock?
You can buy SGT.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Seagen Inc.?
The stock symbol or ticker of Seagen Inc. is SGT.F.
Which industry does the Seagen Inc. company belong to?
The Seagen Inc. industry is Biotechnology.
How many shares does Seagen Inc. have in circulation?
The max supply of Seagen Inc. shares is 188.66M.
What is Seagen Inc. Price to Earnings Ratio (PE Ratio)?
Seagen Inc. PE Ratio is 0.00000000 now.
What was Seagen Inc. earnings per share over the trailing 12 months (TTM)?
Seagen Inc. EPS is 0 EUR over the trailing 12 months.
Which sector does the Seagen Inc. company belong to?
The Seagen Inc. sector is Healthcare.